Fennec Pharma: FDA Grants Fast Track Designation For PEDMARK - Quick Facts

(RTTNews) - Fennec Pharmaceuticals Inc. (FENC) announced the U.S. FDA has granted PEDMARK Fast Track designation for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma.

Rosty Raykov, CEO of Fennec, said: "We believe the receipt of Fast Track designation from the FDA highlights the serious nature of hearing loss that patients have following cisplatin chemotherapy and the current lack of safe and effective treatments. We look forward to the more frequent interactions with the Agency that the Fast Track designation provides, as we prepare for the NDA filing."